RALEIGH, N.C., March 4 /CNW/ -- DARA BioSciences(TM) (Nasdaq: DARA)
announced today the appointment of David J. Drutz, MD to the Board of
Directors. Dr. Drutz was appointed to fill a Board vacancy and will serve on
the Company's Compensation Committee as well as Corporate Governance and
Nominating Committee. The appointment was effective February 26, 2008.
Richard Franco, Sr., DARA's Board Chairman, commented, "It is a pleasure
to announce David's appointment. Considering his varied background and
successful experiences, David will add another positive dimension to our
Dr. Drutz's background includes senior executive positions in the pharma
and biotech industries. He is currently President of Pacific Biopharma
Associates, LLC and a General Partner with Pacific Rim Ventures Company, Ltd.
He serves as a director in both the public and private sectors, is a member of
several scientific advisory boards, and holds a certificate of director
education from the National Association of Corporate Directors.
About DARA BioSciences, Inc.
DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based
development-stage pharmaceutical company that acquires promising therapeutic
molecules and medical technologies directly or through investment in
established companies. DARA focuses its therapeutic development efforts on
small molecules from late preclinical development through phase 2 clinical
trials. DARA is developing a portfolio of therapeutic candidates for
neuropathic pain, metabolic diseases including type 2 diabetes, dyslipidemia
and dermatological disorders. DARA has licensed promising drug development
candidates from Kirin Pharmaceuticals of Japan, Bayer Pharmaceuticals
Corporation, Massachusetts General Hospital and Nuada LLC.
For more information please contact the Company at 919-872-5578 or visit
our web site at www.darabio.com.
All statements in this news release that are not historical are forward-
looking statements within the meaning of the Securities Exchange Act of 1934
as amended. Such forward-looking statements are subject to factors that could
cause actual results to differ materially for DARA from those projected. Those
factors include risks and uncertainties relating to the company's ability to
develop and bring new products to market as anticipated, the current
regulatory environment in which the company develops and sells its products,
the market acceptance of those products, dependence on partner, successful
performance under collaborative and other commercial agreements, competition,
the strength of DARA's intellectual property, the intellectual property of
others and other risk factors identified in the documents DARA has filed, or
will file, with the Securities and Exchange Commission. Copies of DARA's
filings with the SEC may be obtained from the SEC Internet site at
http://www.sec.gov. DARA expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward- looking statements
contained herein to reflect any change in DARA's expectations with regard
thereto or any change in events, conditions, or circumstances on which any
such statements are based. DARA BioSciences and the DARA logo are trademarks
of DARA BioSciences, Inc.
For further information:
For further information: John C. Thomas, Jr., Chief Financial Officer,
+1-919-872-5578; or Lynn H. Morris, Sr. Manager Investor Relations & Corporate
Operations, +1-919-872-5578, both of DARA BioSciences, Inc. Web Site: